Chiara Pautasso

Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis

Stefania Oliva, Manuela Gambella, Milena Gilestro et al. · Oncotarget · 2016 · 36 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Overall Survival Benefit for Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance with Bortezomib-Thalidomide (VMPT-VT) Versus Bortezomib-Melphalan-Prednisone (VMP) in Newly Diagnosed Multiple Myeloma Patients

Antonio Palumbo, Sara Bringhen, Davide Rossi et al. · Blood · 2012 · 35 citations

Medicine, Hematology, Oncology +17

Efficacy and Feasibility of Dose/Schedule-Adjusted Rd-R Vs. Continuous Rd in Elderly and Intermediate-Fit Newly Diagnosed Multiple Myeloma (NDMM) Patients: RV-MM-PI-0752 Phase III Randomized Study

Alessandra Larocca, Marco Salvini, Lorenzo De Paoli et al. · Blood · 2018 · 35 citations

Medicine, Oncology, Pharmacology +10

Association of <scp> <i>RAMP</i> </scp> <i>1</i>   <scp>rs</scp> 7590387 With the Risk of Migraine Transformation Into Medication Overuse Headache

Sarah Cargnin, Chiara Pautasso, Michele Viana et al. · Headache The Journal of Head and Face Pain · 2015 · 19 citations

Medicine, Molecular Genetics, Neurology +15

Long Term Outcome of Lenalidomide-Dexamethasone (Rd) Vs Melphalan-Lenalidomide-Prednisone (MPR) Vs Cyclophosphamide-Prednisone-Lenalidomide (CPR) As Induction Followed By Lenalidomide-Prednisone (RP) Vs Lenalidomide (R) As Maintenance in a Community-Based Newly Diagnosed Myeloma Population: Updated Analysis of EMN01 Phase III Study

Sara Bringhen, Massimo Offidani, Pellegrino Musto et al. · Blood · 2017 · 11 citations

Medicine, Hematology, Oncology +14